J. Joseph Melenhorst, PhD, has been appointed director of Cleveland Clinic’s new cell therapy and immuno-engineering program.
Melenhorst also will serve as vice chair of Center for Immunotherapy and Precision Immuno-Oncology.
He will lead the institution’s cell therapy developmental therapeutics program, with an emphasis on translating research into novel cellular therapies. He also will work with Cleveland Clinic experts to advance immuno-oncology research and treatment.
“Immunotherapy is the future of research in cancer and various other diseases, and Cleveland Clinic has